Q-omics provides the consensus-scored HARS2 profile across patient tissues and cancer cell-line models. HARS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HARS2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HARS2 protein abundance shows 21,993 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KICH, HNSC, and CCRCC as cancer lineages where HARS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HARS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HARS2 survival associations across molecular data types. HARS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HARS2 RNA expression–survival associations across cancer types. High HARS2 expression shows unfavorable associations in KICH, LIHC, CESC and HNSC, but favorable associations in READ and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for HARS2 RNA expression.
This table summarizes HARS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HARS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HARS2 shows higher tumor expression in HNSC, LIHC, LUAD, KIRC, BLCA and KIRP. The HNSC box plot shows higher HARS2 RNA expression in tumor versus normal tissue (log2 FC = +0.742, t-test p < 0.001).
This table shows molecular features associated with HARS2 in patient tissues and cancer cell lines. In patient samples, HARS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HARS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
